生物医药行业投资风险评估研究
发布时间：2018-10-19 19:46
【摘要】：在经济形势日益复杂多变的背景下，生物医药正成为继新能源之后又一个增长最为迅速的高成长性行业之一。21世纪以来，生物技术与信息技术、纳米技术、新材料等其他高技术相互结合，正在形成以基因技术为主要核心的生物医药技术产业链，这就为生物医药的高速良性发展提供了良好的契机。如今，世界上许多国家都不约而同的将生物医药技术作为21世纪科技发展的关键技术，我国也一直将生物医药作为生物技术研究开发的重点。经过几十年的发展，我国的生物医药正摆脱过去跟踪模仿、项目攻坚以及单一技术突破的老路，逐渐向自主研发、产业集群化和全面协调的方向发展。不可否认，我国的生物医药在“先天条件不足”的情况下依然取得了不俗的表现。但是，在成绩的背后，各种问题日益凸显，其中，对投资风险的认识不足导致的投资失败值得关注。然而，尽管目前对投资风险和生物医药其他方面的研究很多，但将两者结合起来研究的却很少，缺乏实用性及可操作性，难以对实践发挥有效的引导作用。因此，加强对生物医药行业投资风险的研究具有很强的现实意义和必要性。 本文以生物医药行业中存在的投资风险为研究对象。在研究方法上不仅采用了传统的规范研究，同时引入了实证研究的方法。结合国内外相关研究，为了更好地评估生物医药的投资风险，笔者以投资风险的来源为依据建立风险评估指标体系，以反映投资风险的影响因素。在指标权重的赋予方式上则采用层次分析法进行赋值，最后运用模糊综合分析法得到生物医药行业投资风险评估的结果。同时，本文以生物芯片、干细胞与再生医学、疫苗与抗体工程和纳米医药为例进行实证检验，运用该评估方法衡量了我国生物医药行业的投资风险水平。研究结果表明，投资生物芯片的风险水平为高风险，投资需谨慎；干细胞与再生医学的投资风险水平为中等风险，可以进行适度投资；疫苗与抗体工程和纳米医药的投资风险都为较高风险。相比前人的研究成果而言，本文在构建生物医药投资风险指标的基础上创建了评估生物医药行业投资风险的研究体系，该体系有利于对生物医药行业的投资风险进行初步判定，并为实际投资作铺垫，也可为政府相关部门制定合理政策、引导生物医药行业健康有序的良性发展提供理论依据。
[Abstract]:In the context of the increasingly complex and changeable economic situation, biomedicine is becoming one of the fastest growing industries after new energy. Since the 21st century, biotechnology and information technology, nanotechnology, The combination of other high technologies such as new materials is forming an industrial chain of biomedical technology with gene technology as the main core which provides a good opportunity for the rapid and benign development of biomedicine. Nowadays, many countries in the world regard biomedical technology as the key technology of the development of science and technology in the 21st century, and our country has always regarded biomedicine as the key point of biotechnology research and development. After decades of development, biomedicine in our country is getting rid of the old way of track imitation, project attacking and single technology breakthrough, and gradually developing to independent R & D, industrial cluster and overall coordination. Undeniably, China's biomedicine has made a good performance under the condition of "insufficient congenital conditions". However, behind the achievements, various problems become increasingly prominent, among which, the investment failure caused by insufficient understanding of investment risk is worthy of attention. However, although there is a lot of research on investment risk and other aspects of biomedicine at present, the combination of the two is seldom studied, lacking practicability and maneuverability, so it is difficult to play an effective guiding role in practice. Therefore, it is of great practical significance and necessity to strengthen the research on investment risk of biomedical industry. This paper takes the investment risk in the biomedical industry as the research object. The research method not only adopts the traditional normative research, but also introduces the empirical research method. In order to better evaluate the investment risk of biomedicine, the author establishes a risk assessment index system based on the source of investment risk to reflect the influencing factors of investment risk. On the way of giving index weight, AHP is used to assign value. Finally, fuzzy comprehensive analysis is used to get the result of investment risk assessment in biomedical industry. At the same time, this paper takes biochip, stem cell and regenerative medicine, vaccine and antibody engineering and nano-medicine as examples to test the investment risk level of biomedical industry in China. The results show that the investment risk level of biochip is high, and the investment level of stem cell and regenerative medicine should be cautious, the investment risk level of stem cell and regenerative medicine is medium risk, and the investment level of stem cell and regenerative medicine can be moderately invested. The investment risk of vaccine and antibody engineering and nano-medicine are both high risk. Compared with the previous research results, this paper establishes a research system to evaluate the investment risk of biomedical industry on the basis of constructing the biomedical investment risk index, which is conducive to the preliminary determination of the investment risk in the biomedical industry. It can also provide theoretical basis for the relevant government departments to formulate reasonable policies and guide the healthy and orderly development of the biomedical industry.
【学位授予单位】：陕西科技大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F275;F426.72
本文编号：2282174
[Abstract]:In the context of the increasingly complex and changeable economic situation, biomedicine is becoming one of the fastest growing industries after new energy. Since the 21st century, biotechnology and information technology, nanotechnology, The combination of other high technologies such as new materials is forming an industrial chain of biomedical technology with gene technology as the main core which provides a good opportunity for the rapid and benign development of biomedicine. Nowadays, many countries in the world regard biomedical technology as the key technology of the development of science and technology in the 21st century, and our country has always regarded biomedicine as the key point of biotechnology research and development. After decades of development, biomedicine in our country is getting rid of the old way of track imitation, project attacking and single technology breakthrough, and gradually developing to independent R & D, industrial cluster and overall coordination. Undeniably, China's biomedicine has made a good performance under the condition of "insufficient congenital conditions". However, behind the achievements, various problems become increasingly prominent, among which, the investment failure caused by insufficient understanding of investment risk is worthy of attention. However, although there is a lot of research on investment risk and other aspects of biomedicine at present, the combination of the two is seldom studied, lacking practicability and maneuverability, so it is difficult to play an effective guiding role in practice. Therefore, it is of great practical significance and necessity to strengthen the research on investment risk of biomedical industry. This paper takes the investment risk in the biomedical industry as the research object. The research method not only adopts the traditional normative research, but also introduces the empirical research method. In order to better evaluate the investment risk of biomedicine, the author establishes a risk assessment index system based on the source of investment risk to reflect the influencing factors of investment risk. On the way of giving index weight, AHP is used to assign value. Finally, fuzzy comprehensive analysis is used to get the result of investment risk assessment in biomedical industry. At the same time, this paper takes biochip, stem cell and regenerative medicine, vaccine and antibody engineering and nano-medicine as examples to test the investment risk level of biomedical industry in China. The results show that the investment risk level of biochip is high, and the investment level of stem cell and regenerative medicine should be cautious, the investment risk level of stem cell and regenerative medicine is medium risk, and the investment level of stem cell and regenerative medicine can be moderately invested. The investment risk of vaccine and antibody engineering and nano-medicine are both high risk. Compared with the previous research results, this paper establishes a research system to evaluate the investment risk of biomedical industry on the basis of constructing the biomedical investment risk index, which is conducive to the preliminary determination of the investment risk in the biomedical industry. It can also provide theoretical basis for the relevant government departments to formulate reasonable policies and guide the healthy and orderly development of the biomedical industry.
【学位授予单位】：陕西科技大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F275;F426.72
【参考文献】
相关期刊论文 前10条
1 李玉彬;钱晓璐;;生物制药产业发展现状与趋势[J];现代农业科技;2010年15期
2 姚宇;侯建明;王欣;;风险投资项目技术风险管理研究[J];工业技术经济;2006年09期
3 徐国胜;陈飞虎;;我国生物医药产业发展现状与策略[J];实用肝脏病杂志;2012年05期
4 王志华;;中国生物医药产业自主创新的维度分析[J];合肥工业大学学报(社会科学版);2010年01期
5 李田,孙平;浅析生物医药行业风险投资[J];科学与管理;2004年03期
6 陆怡;江洪波;;全球生物医药产业现状与发展趋势[J];科学;2012年05期
7 李建纲;我国生物医药产业发展中存在的问题与对策[J];医药世界;2005年01期
8 赵宁;;安泰康:中国生物医药业发展的引擎[J];中国高新技术企业;2010年11期
9 范颂华;;研发型生物医药企业风险投资的价值评价体系研究[J];中国高新技术企业;2011年01期
10 宿凌;;我国生物医药发展模式研究[J];中国药房;2006年02期
相关硕士学位论文 前7条
1 孔雪;风险投资的评价体系研究[D];大连交通大学;2010年
2 朱燕婷;新能源产业投资风险分析与评估体系的构建[D];浙江大学;2011年
3 王伟杰;生物医药产业园试产项目管理研究[D];天津大学;2010年
4 叶碧波;中国生物医药产业创业投资的风险研究[D];天津大学;2010年
5 李代红;风险投资在生物技术产业的投资风险的研究[D];重庆大学;2005年
6 王晓玲;风险投资项目风险控制研究[D];西安科技大学;2006年
7 彭水梅;生物技术风险投资项目评估模型研究[D];湖南科技大学;2010年
，本文编号：2282174
本文链接：https://www.wllwen.com/guanlilunwen/shengchanguanlilunwen/2282174.html
